CNDO News Alert Coronado Biosciences (CNDO) 2.05 12/17/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Coronado Biosciences (CNDO) 2.05 $CNDO

Coronado prices CB Pharma IPO
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 9:58AM CST

CNDO: 2.05 (+0.05)

Coronado Biosciences Announces Pricing of Initial Public Offering of CB Pharma Acquisition Corp.
GlobeNewswire - Mon Dec 15, 7:15AM CST
Coronado Biosciences, Inc. (Nasdaq:CNDO) ("Coronado" or the "Company" reports the pricing on December 12, 2014 of the initial public offering of CB Pharma Acquisition Corp. (Nasdaq:CNLMU) ("CB Pharma" , a company which Coronado founded. CB Pharma is a Cayman Islands exempted company formed as a blank check company for the purpose of entering into a business combination with one or more businesses or entities, with a current focus in the specialty pharma and generic drug industries, among others.
CNDO: 2.05 (+0.05), CNLMU: 10.01 (unch)

Coronado Biosciences, Inc. (CNDO) in Focus: Stock Soars 17.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 8:18AM CST
Coronado Biosciences, Inc. (CNDO) was a big mover last session, as the company saw its shares rise by nearly 18% on the day.
ANIP: 55.08 (+1.32), CNDO: 2.05 (+0.05), AMAG: 40.30 (+1.29), AFFX: 8.90 (+0.10)

Coronado Bio powers up in late trading
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 3:07PM CST

CNDO: 2.05 (+0.05)

Coronado Biosciences (CNDO) Jumps: Stock Rises 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 7:51AM CST
Coronado Biosciences, Inc. (CNDO) was a big mover last session, as its shares rose nearly 9% on the day.
BIIB: 325.13 (-10.67), CNDO: 2.05 (+0.05), ANIP: 55.08 (+1.32), AMAG: 40.30 (+1.29)

Warren Buffett Pick CBI Tumbles On Rating Downgrade
at The Street - Mon Nov 24, 12:00PM CST
Amicus Therapeutics, Inc. (NASDAQ:FOLD), Coronado Biosciences Inc (NASDAQ:CNDO) and Receptos Inc (NASDAQ:RCPT) hit midday posting major gains this Monday. Getting a sluggish start to the week are Fa...
CBI: 37.78 (-0.52), FATE: 3.67 (+0.08), CNDO: 2.05 (+0.05), RCPT: 114.46 (-0.67), FOLD: 7.73 (-0.15)

CB Pharma on deck for IPO
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 10:46AM CST

IPO: 22.40 (-0.17), BIS: 50.05 (+1.20), BIB: 118.31 (-2.94), CNDO: 2.05 (+0.05), IBB: 293.67 (-3.99), DRGS: 52.00 (unch), IXJ: 99.16 (-0.64), IRY: 46.98 (+0.45)

Rackspace Bounces, Making Dan Loeb $34 Million In The Process
at The Street - Tue Nov 11, 1:06PM CST
Coronado Biosciences Inc (NASDAQ:CNDO), Rackspace Hosting, Inc. (NYSE:RAX) and AuRico Gold Inc (NYSE:AUQ) are making notable climbs on the stock market this Tuesday. Town Sports International Holding...
RDUS: 26.30 (+1.20), CLUB: 5.91 (-0.09), RAX: 45.33 (-0.40), CNDO: 2.05 (+0.05), AUQ: 3.08 (-0.12)

InsiderInsights.com Daily Round Up 11/10/14: CHK, TWX, SGEN, PBFX
InsiderInsights - at Seeking Alpha - Tue Nov 11, 2:29AM CST

HAS: 56.90 (+0.70), VR: 40.15 (unch), SEIC: 39.03 (-0.22), DRNA: 13.45 (+0.37), HA: 22.88 (-0.88), SAM: 286.82 (+9.67), PBFX: 19.98 (+0.35), AMRI: 14.19 (-0.75), GSAT: 2.69 (-0.01), TNET: 30.00 (-0.77), TWX: 80.56 (-1.01), HLT: 24.74 (-0.58), Q: 57.17 (+0.12), SGEN: 31.86 (+0.45), CF: 248.87 (+0.88), OPK: 8.70 (-0.16), CHK: 17.45 (+0.23), CNDO: 2.05 (+0.05), CO: 4.31 (+0.16), CPLA: 70.17 (+0.41)

Coronado Biosciences Raises $3,500,000 Through the Private Placement of Restricted Common Stock
GlobeNewswire - Fri Nov 07, 7:38AM CST
Shares were sold at the closing price on November 6, 2014
CNDO: 2.05 (+0.05)

Coronado Biosciences Reports Financial Results
GlobeNewswire - Thu Nov 06, 6:08AM CST
Coronado Biosciences, Inc. (Nasdaq:CNDO) announced its financial results for the third quarter ended September 30, 2014. Coronado's net cash and restricted cash totaled $71.6 million and $15.4 million respectively at September 30, 2014. The Company posted a quarterly net loss of $4.6 million and $16.7 million, or $0.13 and $0.46 per share for the three and nine months ended September 30, 2014 respectively. These results compare to a net loss of $7.8 million and $27.4 million, or $0.24 and $0.95 per share for the three and nine months ended September 30, 2013 respectively.
CNDO: 2.05 (+0.05)

EC approves ulcerative colitis med
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 10:31AM CDT

SGYP: 2.84 (+0.06), JNJ: 102.76 (-1.20), ABT: 43.40 (-0.06), CNDO: 2.05 (+0.05), PFE: 30.67 (-0.19), SHPG: 208.76 (+0.28), VBLX: 11.15 (+0.15), SLXP: 110.11 (+7.08), RCPT: 114.46 (-0.67), ABBV: 65.25 (-0.37), ATHX: 1.23 (-0.04)

Coronado Biosciences Forms Subsidiary to Acquire and License Dermatology Products for Commercialization
GlobeNewswire - Wed Oct 08, 7:35AM CDT
Coronado Biosciences, Inc. (Nasdaq:CNDO) has formed a wholly owned subsidiary, Journey Medical Corporation (JMC), to acquire and license dermatology products. Under the leadership of Claude Maraoui, CEO, JMC will begin building a portfolio of dermatological assets focused on acne, steroid responsive dermatoses, pigmentation and antifungals for promotion to dermatologists and pediatricians.
CNDO: 2.05 (+0.05)

Kamada Plunges Following Missed Marks In Trial
at The Street - Thu Sep 04, 11:52AM CDT
UTi Worldwide Inc. (NASDAQ:UTIW), Flexion Therapeutics Inc (NASDAQ:FLXN) and PVH Corp (NYSE VH) are today's top-gaining billionaire stock picks midday. On the losing end are Kamada Ltd (NASDAQ:KM...
UTIW: 10.74 (-0.06), FLXN: 18.99 (+0.14), CNDO: 2.05 (+0.05), KMDA: 3.57 (+0.02), CIEN: 18.06 (-0.07), PVH: 121.69 (-4.71)

Coronado Falls on TSO Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 10:20AM CDT
Coronado (CNDO) announced disappointing top-line results from a pilot study on TSO.
BIIB: 325.13 (-10.67), MDCO: 26.38 (+1.24), CNDO: 2.05 (+0.05), REGN: 396.13 (-4.88)

Coronado Biosciences Reports Topline Results From Investigator Initiated Pilot Study of TSO in Adults With Autism Spectrum Disorder
GlobeNewswire - Thu Jun 26, 7:50AM CDT
Coronado Biosciences, Inc. (Nasdaq:CNDO) today announced that Dr. Eric Hollander, Clinical Professor Psychiatry and Behavioral Sciences at Albert Einstein College of Medicine of Yeshiva University and Director of the Autism and Obsessive Compulsive Spectrum Program at Montefiore Medical Center and Einstein has completed his pilot study of oral TSO (Trichuris suis ova or CNDO-201) for adults with Autism Spectrum Disorder (ASD).
CNDO: 2.05 (+0.05)

Autism - Pipeline Review, H1 2014 - 20 Companies & 42 Drug Profiles
M2 - Fri Jun 20, 2:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ltzhjv/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Dainippon Sumitomo Pharma Co., Ltd. - Novartis AG - Merz Pharma GmbH & Co. KgaA - Teva Pharmaceutical Industries Limited - Avanir Pharmaceuticals, Inc. - Snowdon Inc. - Curemark, LLC - Coronado Biosciences, Inc. - Omeros Corporation - Intra-Cellular Therapies, Inc. - Cellceutix Corporation - Heptares Therapeutics Ltd. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Naurex, Inc. - Nectid, Inc. - Mnemosyne Pharmaceuticals, Inc. - BioCrea GmbH - Saniona AB Drug Profiles - CM-AT - lurasidone hydrochloride - aripiprazole - cycloserine - fluoxetine - oxytocin - oxytocin - memantine hydrochloride - TSO - pioglitazone hydrochloride - oxytocin - oxytocin - (dextromethorphan hydrobromide quinidine sulfate) - oxytocin - oxytocin - RG-7314 - fluoxetine - fluoxetine - argipressin tannate - NU-211-01 NC-215-01 - Autologous Hematopoietic Stem Cells - glatiramer acetate - ITI-007 - Stem Cell Therapy for Central Nervous System Disorders - KM-391 - Program For Neurological Disorders - STX-110 - CN-2097 - acamprosate calcium - Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome For more information visit http://www.researchandmarkets.com/research/lt...m_pipeline
CNDO: 2.05 (+0.05), TEVA: 55.15 (-0.47), ITCI: 15.75 (+0.08), OMER: 20.51 (-0.62), NVS: 91.65 (+0.01)

Global Autism Clinical Trials Review 2014
M2 - Tue Jun 17, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vhfbw6/autism_global) has announced the addition of the "Autism Global Clinical Trials Review, H1, 2014" report to their offering. Autism Global Clinical Trials Review, H1, 2014 provides data on the Autism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Autism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Autism. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Autism Speaks, Inc. - Seaside Therapeutics, LLC - Forest Laboratories, Inc. - Johnson & Johnson - Otsuka Holdings Co., Ltd. - F. Hoffmann-La Roche Ltd. - Bristol-Myers Squibb Company - Coronado Biosciences, Inc. - ZonMw - Dainippon Sumitomo Pharma Co., Ltd. - National Institute of Mental Health - Massachusetts General Hospital - Tehran University of Medical Sciences - Eunice Kennedy Shriver National Institute of Child Health and Human Development - Hugo W. Moser Research Institute at Kennedy Krieger, Inc. - Stanford University - The University of Hong Kong - University of California, Los Angeles - Mount Sinai Hospital - University of California, San Francisco For more information visit http://www.researchandmarkets.com/research/vh...ism_global
JNJ: 102.76 (-1.20), CNDO: 2.05 (+0.05), BMY: 57.69 (-0.86), FRX: 99.00 (-0.77)

Arkansas Leading Change in College Student Experience
Marketwire - Tue Feb 25, 6:04AM CST
Today, Achieving the Dream released Continuous Improvement for College Completion: Arkansas Builds a System-Level Strategy for Community College Student Success during a session at DREAM 2014. This report details the coordinated efforts of Arkansas that has significantly improved the progress of student outcomes at two-year colleges across the state.
CNDO: 2.05 (+0.05)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 140

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 203

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 71

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 95

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 126

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 78

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 116

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 172

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading

Top 5 Most Recently Viewed Articles

Bitcoin Faces Criticism While BlackRock Sees Financial Success

Updated Category News Views 167

Bitcoin Under Scrutiny In recent discussions, Peter Schiff has taken to social media to share his critical views on Bitcoin, branding it as a "fake asset." His assertion comes after Bitcoin's price retracement from its historic highs, indicating a significant downturn. Currently, Bitcoin is trading at around $81,000 after once peaking at $110,000. Schiff argues that the...

Continue Reading
Valneva Secures $32.8 Million Contract for IXIARO Vaccine Supply

Updated Category News Views 213

Valneva Expands IXIARO Vaccine Supply with New Contract Valneva SE, a leading specialized vaccine company, has officially announced a significant step forward in its partnership with the U.S. Department of Defense (DoD) by signing a new contract valued at a minimum of $32.8 million for the IXIARO vaccine. This substantial agreement marks another chapter in Valneva's...

Continue Reading
EFGH and Minerva Forge Strategic Partnership for Data Centres

Updated Category News Views 118

EFGH and Minerva Unite to Enhance Ghana's Digital Landscape In a landmark agreement, Embed Financial Group Holdings (EFGH) has joined forces with Minerva Data Limited, a prominent player in digital infrastructure, to create advanced data centres and strengthen the technology ecosystem in Ghana. This collaboration marks a significant step in addressing the growing demand...

Continue Reading
Landsea Homes Achieves Remarkable Growth in Q3 Results

Updated Category News Views 50

Strong Financial Performance in Q3 Landsea Homes Corporation (NASDAQ: LSEA) reported impressive financial results for the third quarter, demonstrating robust performance in the residential homebuilding sector. For the quarter, Landsea Homes achieved a net income of $11.1 million, translating to $0.30 per share. This marks a 29% increase in net income compared to the...

Continue Reading
Urban Logistics REIT: Key Disclosure Insights for Investors

Updated Category News Views 219

Understanding the Disclosure from Urban Logistics REIT In the realm of public trading, disclosures play a pivotal role in keeping investors informed about changes in significant stakes within companies. Recently, Urban Logistics REIT Plc, underlining its commitment to transparency, provided valuable insights through its disclosure concerning investor positions, managed by...

Continue Reading